Mode
Text Size
Log in / Sign up

Retrospective cohort study assesses delta-NLR and baseline NLR for prognosis in soft tissue sarcoma.

Retrospective cohort study assesses delta-NLR and baseline NLR for prognosis in soft tissue sarcoma.
Photo by Dmytro Vynohradov / Unsplash
Key Takeaway
Note delta-NLR associated with prognosis in soft tissue sarcoma, but observational design limits causal inference.

This retrospective cohort study was conducted at the Musculoskeletal Tumor Center of The First Affiliated Hospital of Zhengzhou University. The population consisted of 231 specific patients with soft tissue sarcoma. Follow-up duration included three- and five-year intervals for assessing overall prognosis.

The intervention or exposure involved dynamic neutrophil-to-lymphocyte ratio (delta-NLR) and baseline NLR. Comparators included baseline NLR alone, other hematologic parameters, and clinical characteristics. The primary outcome focused on prognosis defined as overall survival. Secondary outcomes included predictive accuracy and clinical utility.

Main results showed delta-NLR possessed greater predictive accuracy relative to other hematologic parameters and clinical characteristics. Independent predictors of prognosis included FNCLCC grade, patient age, and delta-NLR. The nomogram C-index was 0.702. Categorization based on delta-NLR trends identified an NLR increase group (n=94) and NLR decrease group (n=137) respectively.

Safety data regarding adverse events, serious adverse events, discontinuations, and tolerability were not reported. Limitations were not reported in the source material. Practice relevance suggests utilizing this delta-NLR-based nomogram may offer substantial clinical utility in the management of STS. Clinicians should note the observational nature of the current evidence provided in this report.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundSoft tissue sarcomas (STS) exhibit significant heterogeneity and are classified as rare tumors with a high risk of metastasis. The neutrophil-to-lymphocyte ratio (NLR), a hematological marker indicative of systemic inflammation, has gained broad recognition for its prognostic utility in oncology. This ratio can be used to evaluate the dynamic changes in inflammatory markers during the diagnosis and treatment of tumors. The value of NLR fluctuations in STS has yet to be fully investigated.MethodsThis investigation involved a retrospective cohort of 231 patients with STS, all definitively diagnosed and managed at the Musculoskeletal Tumor Center of The First Affiliated Hospital of Zhengzhou University, aiming to evaluate their clinical profiles. The research focused on analyzing the impact of both baseline NLR and its dynamic changes throughout therapy on the prognostic outcomes in STS, with the aim of constructing a nomogram based on delta-NLR.ResultsThe study cohort comprised 231 individuals diagnosed with STS. Based on delta-NLR trends, participants were categorized into two cohorts: an NLR increase group (n=94) and an NLR decrease group (n=137). Analysis using time-dependent receiver operating characteristic (ROC) curves revealed that delta-NLR possessed greater predictive accuracy for prognosis relative to other hematologic parameters and clinical characteristics. Both univariate and multivariate analyses determined that Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grade, patient age, and delta-NLR served as independent predictors of prognosis. A prognostic nomogram was subsequently constructed integrating these significant factors. The nomogram achieved a C-index of 0.702, and calibration curves verified its accuracy in predicting three- and five-year overall survival (OS) for STS patients. Results from decision curve analysis (DCA) and clinical impact curve assessment additionally validated that utilizing this delta-NLR-based nomogram may offer substantial clinical utility in the management of STS.ConclusionNLR is valuable for continuous monitoring, and ongoing assessment of NLR provides better survival predictions for patients with STS than using baseline NLR alone.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.